Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Venture capital funding driving demand for CFOs

In Connecticut, startups — predominantly technology or life sciences ventures located in Greater New Haven — hauled in more than $707 million in funding in...

| By Kelley Gipson

Thetis adds to cancer program and SAB

Thetis Pharmaceuticals reports the launch of a new program in cancer. Thetis CEO Gary Mathias said, “We are targeting pancreatic, metastatic colorectal, small cell lung...

| By Kelley Gipson

UConn studying jaw pain, solid tumors

Pain where the jaw hinges to the skull is both common and difficult to treat. Killing off aged cells might be the secret to healing...

| By Kelley Gipson

Bioais reports positive results re multiple sclerosis

Bioais has reported positive results from an efficacy study of a blood-brain barrier penetrant interleukin-1 receptor inhibitor in a preclinical rodent model of multiple sclerosis....

| By Kelley Gipson

Rallybio to go public in $100M IPO

Less than four years after a team of former Alexion Pharmaceuticals executives launched a startup to develop new therapies for severe and rare disorders, their...

| By Kelley Gipson

Sosei and InveniAI in drug discovery collaboration

InveniAI andi Sosei Group have announced a new R&D collaboration. The collaboration will combine InveniAI’s AI-powered platform, AlphaMeld®, for target discovery with Sosei Heptares’ G-protein...

| By Kelley Gipson

UConn plan would promote research and startups

A proposal authorizing $47 million in bond funds over five years for what UConn officials have termed “innovation faculty hires” was added to a bonding...

| By Kelley Gipson

Executives named at Hyperfine, Bioasis

Bioasis, which is developing iproprietary platform technology for the delivery of therapeutics across the blood-brain barrier, has announced the appointment of Dave Jenkins as Chief Financial...